KIRKLAND, WA-- Cardiac Dimensions®, Inc. today announced that an update to its landmark TITAN clinical trial will be given as part of the 23rd annual Transcathether Cardiovascular Therapeutics (TCT) ...
Cardiac Dimensions, a Kirkland, Wash., company with a technology to treat heart valve malfunction, has raised $53 million from investors.… Read More Cardiac Dimensions, a medical device company based ...
KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for patients with heart failure, today announced the company has closed a ...
Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System® KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions®, a leader ...
Cardiac Dimensions, a medical device company based in Kirkland, Wash., landed $35 million to support testing and marketing of its system to treat mitral valve regurgitation. Mitral valve regurgitation ...
KIRKLAND, Washington, Sept. 2, 2020 /PRNewswire/ -- Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients ...
KIRKLAND, Wash.-- Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today ...
Ahead of the Transcatheter Cardiovascular Therapeutics (TCT) 2018 conference, Kirkland, Wash.-based Cardiac Dimensions Inc. reported the randomization of the first patient in the CARILLON pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results